PLX-51107 by Plexxikon for Graft Versus Host Disease (GVHD): Likelihood of Approval
PLX-51107 is a drug candidate under development by Plexxikon for the treatment of chronic lymphocytic leukemia, acute myeloid leukemia, graft versus host disease (GVHD), high-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasm. It is a small molecule that acts by targeting BRD4.
PLX-51107 is currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.
Link to the original story: https://www.pharmaceutical-technology.com/uncategorized/plx-51107-plexxikon-graft-versus-host-disease-gvhd-likelihood-of-approval-2/
Using RFID and IoT for Asset Tracking
Firm launches 5G phone to boost adoption
OnePlus 12 gets a slight price increase, 12R matches Pixel 7a
About The Author
boB
Well, hey there! The name's boB, and I hail from the humble town of boBsville. I'm a bit of a jack-of-all-trades, you know? I enjoy tinkering around with gadgets, exploring the great outdoors, and meeting new people. If you have any questions or just want to chat, feel free to hit me up!